Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last4,601 to 4,620 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| MMRV (AMP) vs MMRV (2006 Process): serious adverse events | 21 of 682 18 of 683 | 0.4 points -1.4 to 2.3 | 1,365 | NCT01536405 Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027) |
| V181 vs Butantan - DV: deaths from any cause | 1 of 682 0 of 682 | 0.1 points -0.4 to 0.8 | 1,364 | NCT05710224 Clinical Bridging Study Between V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated]) to Butantan Dengue Vaccine (Butantan - DV) in Healthy Adults 18 to 50 Years of Age in Brazil (V181 - 002) |
| Shared Decision Making/Brief Negotiated Interviewing vs Control Arm: serious adverse events | 5 of 678 0 of 684 | 0.7 points 0.0 to 1.7 | 1,362 | NCT02910089 ENhancing Outcomes Through Goal Assessment and Generating Engagement in Diabetes Mellitus |
| ESO 40 mg vs RAB ER 50 mg: serious adverse events | 6 of 676 3 of 685 | 0.4 points -0.5 to 1.5 | 1,361 | NCT00658632 Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD) |
| Hydroxychloroquine vs Placebo: serious adverse events | 3 of 683 2 of 677 | 0.1 points -0.7 to 1.0 | 1,360 | NCT04334148 Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine |
| Rimegepant (Users With <12 Days of Use) vs Triptans: Number of Participants With Hospitalizations in Past 6 Months- Sensitivity Analysis | 11 of 103 111 of 1,257 | 1.8 points -3.1 to 9.4 | 1,360 | NCT06680206 Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey |
| Rimegepant (Users With <12 Days of Use) vs Triptans: Number of Participants With Neurologist Visits in Past 6 Months- Sensitivity Analysis | 57 of 103 358 of 1,257 | 26.9 points 16.9 to 36.4 | 1,360 | NCT06680206 Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey |
| Rimegepant (Users With <12 Days of Use) vs Triptans: Number of Participants With Emergency Room (ER) Visits in Past 6 Months- Sensitivity Analysis | 27 of 103 301 of 1,257 | 2.3 points -5.6 to 11.8 | 1,360 | NCT06680206 Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey |
| Rimegepant (Users With <12 Days of Use) vs Triptans: Number of Participants With Cardiologist Visits in Past 6 Months- Sensitivity Analysis | 14 of 103 137 of 1,257 | 2.7 points -2.9 to 10.8 | 1,360 | NCT06680206 Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey |
| Rimegepant (Users With <12 Days of Use) vs Triptans: Number of Participants With Family Practitioner Visits in Past 6 Months- Sensitivity Analysis | 76 of 103 976 of 1,257 | -3.9 points -13.4 to 4.0 | 1,360 | NCT06680206 Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey |
| Rimegepant (Users With <12 Days of Use) vs Triptans: Number of Participants With Traditional Healthcare Provider Visits in Past 6 Months- Sensitivity Analysis | 101 of 103 1,227 of 1,257 | 0.4 points -4.5 to 2.2 | 1,360 | NCT06680206 Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey |
| Intervention-hypo vs Control-standard Care: serious adverse events | 547 of 688 513 of 671 | 3.1 points -1.4 to 7.5 | 1,359 | NCT00391469 Induction of Mild Hypothermia Following Out-of-hospital Cardiac Arrest |
| Hydroxychloroquine vs Placebo: Number of Participants With Serious Adverse Events (SAEs) or Hydroxychloroquine-Associated Events of Special Interest (EOSIs) | 7 of 683 8 of 676 | -0.2 points -1.4 to 1.1 | 1,359 | NCT04334148 Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine |
| Hydroxychloroquine vs Placebo: Number of Participants With Clinical Infection With COVID-19 Infection | 41 of 683 53 of 676 | -1.8 points -4.6 to 0.9 | 1,359 | NCT04334148 Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine |
| Hydroxychloroquine vs Placebo: Number of Participants With COVID-19 Viral Shedding | 2 of 683 2 of 676 | -0.0 points -0.8 to 0.8 | 1,359 | NCT04334148 Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine |
| MVI 200 vs Dinoprostone Vaginal Insert (DVI): serious adverse events | 130 of 678 107 of 680 | 3.4 points -0.6 to 7.5 | 1,358 | NCT01127581 Efficacy & Safety Study Comparing Misoprostol Vaginal Insert (MVI) Versus Dinoprostone Vaginal Insert (DVI) for Reducing Time to Vaginal Delivery |
| High Dose Vitamin D Formulation vs Placebo: serious adverse events | 14 of 690 18 of 668 | -0.7 points -2.4 to 1.0 | 1,358 | NCT03096314 Vitamin D to Improve Outcomes by Leveraging Early Treatment |
| V181 vs Butantan - DV: serious adverse events | 12 of 680 9 of 678 | 0.4 points -1.0 to 1.9 | 1,358 | NCT05710224 Clinical Bridging Study Between V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated]) to Butantan Dengue Vaccine (Butantan - DV) in Healthy Adults 18 to 50 Years of Age in Brazil (V181 - 002) |
| Sustained Care vs Standard Care: Tobacco Abstinence - 6 Month Follow-up | 113 of 680 105 of 677 | 1.1 points -2.8 to 5.0 | 1,357 | NCT01714323 Comparative Effectiveness of Post-Discharge Strategies for Hospitalized Smokers |
| Sustained Care vs Standard Care: All-cause Mortality | 13 of 680 14 of 677 | -0.2 points -1.7 to 1.4 | 1,357 | NCT01714323 Comparative Effectiveness of Post-Discharge Strategies for Hospitalized Smokers |
Code
curl "https://conductscience.org/api/comparisons/v1?page=231"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=231
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT01536405-sae",
"title": "MMRV (AMP) vs MMRV (2006 Process): serious adverse events",
"summary": "21 of 682 against 18 of 683; risk difference 0.4 points, 95% interval -1.4 to 2.3; NCT01536405, Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027)",
"record": "/library/comparisons/NCT01536405-sae",
"nct_id": "NCT01536405",
"kind": "serious-adverse-events",
"participants": 1365,
"risk_difference": {
"value": 0.004437469676217137,
"lower": -0.013843021046426027,
"upper": 0.022953996493854587
},
"group_1": "21 of 682",
"group_2": "18 of 683",
"difference": "0.4 points",
"interval": "-1.4 to 2.3",
"trial_title": "Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027)"
},
{
"id": "NCT05710224-deaths",
"title": "V181 vs Butantan - DV: deaths from any cause",
"summary": "1 of 682 against 0 of 682; risk difference 0.1 points, 95% interval -0.4 to 0.8; NCT05710224, Clinical Bridging Study Between V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated]) to Butantan Dengue Vaccine (Butantan - DV) in Healthy Adults 18 to 50 Years of Age in Brazil (V181 - 002)",
"record": "/library/comparisons/NCT05710224-deaths",
"nct_id": "NCT05710224",
"kind": "deaths",
"participants": 1364,
"risk_difference": {
"value": 0.001466275659824047,
"lower": -0.004263471030847753,
"upper": 0.008258333937551803
},
"group_1": "1 of 682",
"group_2": "0 of 682",
"difference": "0.1 points",
"interval": "-0.4 to 0.8",
"trial_title": "Clinical Bridging Study Between V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated]) to Butantan Dengue Vaccine (Butantan - DV) in Healthy Adults 18 to 50 Years of Age in Brazil (V181 - 002)"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=232",
"request_id": "kwfRZ7B22pecidbQ"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
The conductscience.com catalog
One instrument from the ConductScience store with the tests, measures and species it is used for, the papers that used it, and the MeSH topics of those papers.
Open Targets
One drug with its targets, the diseases it is studied for, and the trials that name it, with their comparisons, papers and cognitive tests.
Open Targets
One disease with the drugs studied for it, the targets those drugs act on, and the trials that study it, with their comparisons and papers.
ClinicalTrials.gov
One company with the trials it leads or helps run, the drugs those trials test, the conditions they study and the organizations it runs them with.
Cellosaurus
One cell line with the problems Cellosaurus records for it, its relatives, the cell banks that hold it, and the papers that used it.
PubMed and NLM's journal list
One journal with its papers in PubMed since 1959, year by year, its retracted papers, errata and expressions of concern, and how many of its papers have a copy in PMC.
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant